- 米国企業
- Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc.APLS
| 2017年
12月31日 | 2018年
12月31日 | 2019年
12月31日 | 2020年
12月31日 | 2021年
12月31日 | 2022年
12月31日 |
|---|
| Product | - | - | - | - | 15 | 65 |
|---|
| Licensing and other revenue | - | - | - | - | 51 | 10 |
|---|
| Revenue | - | - | - | 251 | 67 | 75 |
|---|
| Cost of sales | - | - | - | - | 0 | 6 |
|---|
| Research and development | - | 105 | 221 | 300 | 346 | 387 |
|---|
| Cost of research collaboration | - | - | - | - | 75 | - |
|---|
| License expense | - | - | - | 25 | 5 | - |
|---|
| General and administrative | 10 | 23 | 67 | 139 | 177 | 277 |
|---|
| Total Operating expenses: | - | - | - | 464 | 603 | 670 |
|---|
| Net operating loss | -50,767,029 | -127,924,760 | -288,015,253 | -214 | -536 | -595 |
|---|
| Loss on conversion of debt | - | - | - | - | 101 | 33 |
|---|
| Derivative, Gain (Loss) on Derivative, Net | - | - | -14,839,000 | -103 | -98 | - |
|---|
| Interest income | - | 3 | 5 | 4 | 0 | 9 |
|---|
| Interest expense | - | 3 | 5 | 30 | 13 | 33 |
|---|
| Other(expense)/ income, net | - | -110,758 | -175,314 | -1 | 1 | -0 |
|---|
| Net loss before taxes | - | - | - | -343 | -746 | -652 |
|---|
| Income tax expense | - | - | - | 2 | 0 | 1 |
|---|
| Net loss | -51,006,094 | -127,502,194 | -304,706,613 | -345 | -746 | -652 |
|---|
| Unrealized (loss)/gain on marketable securities | - | - | - | -0 | 0 | -0 |
|---|
| Unrealized gain on pension plans | - | - | - | - | - | 2 |
|---|
| Foreign currency (loss)gain | - | -122,807 | -30,968 | 0 | -2 | -0 |
|---|
| Total other comprehensive income/(loss) | - | -122,807 | -30,968 | 0 | -2 | 1 |
|---|
| Comprehensive loss, net of tax | - | -127,625,001 | -304,737,581 | -345 | -748 | -651 |
|---|
| Earnings Per Share, Basic | - | - | - | - | - | -6.15 |
|---|
| Earnings Per Share, Diluted | - | - | - | - | - | -6.15 |
|---|